Current Edition

news

Vertex, CRISPR gene-editing therapy hit with clinical hold

U.S. regulators have placed a clinical hold on CRISPR Therapeutics’ lead candidate, spurring a double-digit drop in the Swiss biotech’s stock value by Thursday morning. …

Continue Reading →